RELMADA THERAPEUTICS, INC. (OTCMKTS:RLMD) Files An 8-K Other Events

RELMADA THERAPEUTICS, INC. (OTCMKTS:RLMD) Files An 8-K Other Events
Item 8.01. Other Events  

Relmada Therapeutics, Inc. (the “Company”) previously disclosed in a Form 10-K for the year ended on June 30, 2019 filed with the Securities and Exchange Commission on September 24, 2019 that (i) in September 2019, 75,000 common stock warrants with an exercise price of $6.00 per share were exercised, for net proceeds of $450,000, and (ii) on September 23, 2019, the Company closed on a private placement of equity securities to Share Purchase Agreements and Subscription Agreements, dated September 23, 2019. The price per share was $7.00. The Company issued an aggregate of 75,108 shares of common stock in this closing, for net proceeds of $525,750. On September 26, 2019, the Company closed on an additional private placement of equity securities to a Share Purchase Agreement and Subscription Agreement. The price per share was $7.00. The Company issued an aggregate of 42,857 shares of common stock in this closing, for net proceeds of $300,000. (The numbers of shares and prices per share herein have been adjusted to give effect to the previously announced 1-for-4 reverse split of our common stock that became effective on September 30, 2019.)

Attached hereto as Exhibit 99.1 is a proforma balance sheet as of June 30, 2019 giving effect to the receipt by the Company of the proceeds from the warrant exercises and receipt by the Company of the net proceeds from the closing of the offerings.

Item 9.01. Financial Statements and Exhibits.

99.1 Proforma balance sheet as of June 30, 2019.


RELMADA THERAPEUTICS, INC. Exhibit
EX-99.1 2 f8k092619bex99-1_relmada.htm PROFORMA BALANCE SHEET AS OF JUNE 30,…
To view the full exhibit click here

Story continues below

About RELMADA THERAPEUTICS, INC. (OTCMKTS:RLMD)

Relmada Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in developing a pipeline of drug candidates to treat chronic pain. Its product candidates include d-Methadone (dextromethadone, REL-1017), LevoCap ER (REL-1015), BuTab (REL-1028) and MepiGel (REL-1021). Its d-Methadone is an N-methyl-D-aspartate (NMDA) receptor antagonist being developed for the treatment of neuropathic pain. Its REL-1015 is an extended release, abuse deterrent formulation of the opioid analgesic levorphanol, which is pharmacologically differentiated from morphine, oxycodone and other opioids for the management of pain severe enough to require daily, around-the-clock and long-term opioid treatment. REL-1028 represents formulations of oral, modified release buprenorphine being developed for both chronic pain and opioid dependence indications. REL-1021 is a topical dosage form of the local anesthetic mepivacaine for the treatment of painful peripheral neuropathies.

An ad to help with our costs